Melanotan I

FDA Approved

Melanotan I (Afamelanotide)

Aliases
Afamelanotide, Scenesse
Administration
Subcutaneous implant (FDA-approved route)

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    In its approved implant form, users typically notice increased sun tolerance within the first couple of weeks.

  2. 2

    3–4 Weeks

    Skin pigmentation changes are commonly visible by this stage.

  3. 3

    5–7 Weeks

    The effects of a single implant are generally expected to remain steady through this window.

  4. 4

    8–10 Weeks

    Sun tolerance and pigmentation benefits typically continue through the implant's roughly two-month duration.

  5. 5

    11–15 Weeks

    A second implant is commonly administered around this time to maintain effects, per approved dosing.

  6. 6

    16–20 Weeks

    With repeat dosing, users typically report consistent, maintained photoprotection.

  7. 7

    21–24 Weeks

    By this stage, most patients on approved therapy are in a steady maintenance pattern.

⚠️ Research context only. This is not medical advice and results are not guaranteed.